MannKind Corporation's inhaled insulin formulation Afrezza drew attention at the American Diabetes Association (ADA) Scientific Sessions 2026, where a cluster of clinical and real-world studies examined the product's performance across pediatric patients, pregnant individuals, and users of automated insulin delivery (AID) systems. The breadth of the data package signals a sustained push to expand Afrezza's clinical evidence base beyond its original adult, non-pregnant indication.
Afrezza delivers recombinant human insulin via a dry-powder inhalation mechanism using MannKind's proprietary Technosphere particle platform, which is engineered for rapid pulmonary absorption. The technology is designed to achieve a pharmacokinetic profile that more closely mirrors physiological first-phase insulin release than conventional subcutaneous rapid-acting analogs — a bioavailability distinction that carries meaningful implications for postprandial glucose control. Published peer-reviewed work has previously demonstrated faster time-to-peak insulin concentration compared to injectable rapid-acting formulations, though head-to-head clinical endpoints across the newly presented populations remain under active investigation.
The ADA 2026 presentations are particularly notable for their focus on populations historically underrepresented in inhaled-insulin research. Pediatric data is especially consequential given that type 1 diabetes management in children involves distinct dosing, adherence, and safety considerations. Meanwhile, AID system compatibility data addresses a fast-growing segment of the diabetes device market, as closed-loop and hybrid closed-loop systems have seen accelerating adoption. Pregnancy data, if robust, could open a meaningful — and highly regulated — new-use corridor for the product, though any label expansion would require separate regulatory review by FDA.
From a functional nutrition and nutraceutical industry standpoint, Afrezza occupies a unique border zone: it is an FDA-approved drug, not a dietary supplement or food-derived ingredient, and therefore operates entirely outside the GRAS, NDI, or structure-function claim framework. However, the underlying Technosphere pulmonary-delivery platform has drawn periodic interest from ingredient innovators exploring inhalation as a bioavailability-enhancement route for functional compounds. The ADA data package could reinforce broader industry conversations about pulmonary bioavailability as a delivery mechanism worthy of serious formulation investment. Distribution of Afrezza remains through pharmacy and specialty channels, not finished-formulation or white-label co-manufacturing pipelines.
Operators and formulators tracking the glucose-management category — one of the most active segments in functional foods, spanning chromium-enriched products and berberine formulations to postbiotic and fiber-based glycemic-support SKUs — will want to monitor how expanded real-world Afrezza evidence shapes clinical guidelines, consumer expectations around glucose kinetics, and ultimately the claims landscape for food-adjacent metabolic-health products. Coverage is produced in partnership with Food & Beverage Magazine.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.